Save up -80% on Abciximab
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Abciximab
Reopro 2 mg/ml vial
|price without discount in nearest pharmacy. Price may vary.|
We offer free Abciximab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Abciximab every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Abciximab volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Abciximab
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (.v.3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Abciximab mechanism of action
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the .v.3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.
Dosage forms of Abciximab
|Injection, solution||intravenous||2 mg/mL|
7E3 7E3 antibody
Eli Lilly and Company
Humans and other mammals
Indication of Abciximab
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
Toxicity of Abciximab
RX24 Drugs Disclaimer: before buying a Abciximab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.